New Study Highlights BulbiCAM’s Potential in Parkinson’s Disease Monitoring
A new study published in the Journal of Parkinson’s Disease demonstrates that BulbiCAM can detect measurable differences in the pupillary light reflex in individuals with Parkinson’s disease.
The study was conducted at Oslo University Hospital as part of the PROSPOS study (Prospective Observational Study of Parkinsonism). The findings show that the observed differences are not influenced by medication, suggesting that these measurements may provide a valuable objective marker for monitoring disease progression over time.
The publication represents an important addition to the growing body of clinical evidence supporting BulbiCAM and reinforces Bulbitech’s commitment to developing objective tools for neurological assessment and disease monitoring.